Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine
To assess the efficacy, safety, and predictors for poor responsiveness of botulinum toxin type A (BoNT-A) for chronic migraine in the adolescent and young adult population. A retrospective analysis of 56 patients who received BoNT-A for chronic migraine with an age range from 13 to 21 years was perf...
Gespeichert in:
| Veröffentlicht in: | Pediatric neurology 2022-05, Vol.130, p.21-27 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 27 |
|---|---|
| container_issue | |
| container_start_page | 21 |
| container_title | Pediatric neurology |
| container_volume | 130 |
| creator | Goenka, Ajay Grace Yu, Sarah Chikkannaiah, Mahesh George, Monica Cathryn MacDonald, Sarah Stolfi, Adrienne Kumar, Gogi |
| description | To assess the efficacy, safety, and predictors for poor responsiveness of botulinum toxin type A (BoNT-A) for chronic migraine in the adolescent and young adult population.
A retrospective analysis of 56 patients who received BoNT-A for chronic migraine with an age range from 13 to 21 years was performed. Of 56 patients, 34 were enrolled in the study based on the inclusion criterion. Patients who received three dosages of BoNT-A were assessed at nine months from the first injection. Variables including age, body mass index, headache intensity, frequency, character, and side effects were assessed. The patients were divided into two groups based on response to BoNT-A therapy, responders and nonresponders.
Overall among the 34 patients enrolled in the study, the average headache frequency decreased from 18.6 of 28 to 9.9 of 28 days, P value, |
| doi_str_mv | 10.1016/j.pediatrneurol.2022.02.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2640995884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0887899422000200</els_id><sourcerecordid>2640995884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-df48e7656918650f1d31b77b3895710205dcde70263dbe002d39a1a28bd9279f3</originalsourceid><addsrcrecordid>eNqNkE1v1DAQhi0EokvhLyBLXLhkO7bjxIbTUkqL1IoKLWcrsSfgVTYOdlJ1--txlVKpt0pj-_J-jB9CPjBYM2DVyW49ovPNFAecY-jXHDhfQx7gL8iKqVoUkkl4SVagVF0orcsj8ialHQBIzcvX5EhIAVIyWJG7cxwwNr2_Q0c3w63H6UC_-hSiw_iJbuh1zGV2CpF2-VyHfP3ENIYh-ZtsTYlOgX4J09z7Yd7Tbbj1A90eRsze7Z8cPR4W57Kzt_TK_46NH_AtedU1fcJ3D-8x-fXtbHt6UVz-OP9-urksrFBiKlxXKqwrWWmmKgkdc4K1dd0KpWXNgIN01mENvBKuxQzBCd2whqvWaV7rThyTj0vuGMPfGdNk9j5Z7PtmwDAnw6sStJZKlVn6eZHaGFKK2Jkx-n0TD4aBuYdvduYJfHMP30Ae4Nn9_qFobvfoHr3_aWfB2SLA_N0bj9Ek63GwOTGinYwL_llF_wDtF56k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640995884</pqid></control><display><type>article</type><title>Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Goenka, Ajay ; Grace Yu, Sarah ; Chikkannaiah, Mahesh ; George, Monica Cathryn ; MacDonald, Sarah ; Stolfi, Adrienne ; Kumar, Gogi</creator><creatorcontrib>Goenka, Ajay ; Grace Yu, Sarah ; Chikkannaiah, Mahesh ; George, Monica Cathryn ; MacDonald, Sarah ; Stolfi, Adrienne ; Kumar, Gogi</creatorcontrib><description>To assess the efficacy, safety, and predictors for poor responsiveness of botulinum toxin type A (BoNT-A) for chronic migraine in the adolescent and young adult population.
A retrospective analysis of 56 patients who received BoNT-A for chronic migraine with an age range from 13 to 21 years was performed. Of 56 patients, 34 were enrolled in the study based on the inclusion criterion. Patients who received three dosages of BoNT-A were assessed at nine months from the first injection. Variables including age, body mass index, headache intensity, frequency, character, and side effects were assessed. The patients were divided into two groups based on response to BoNT-A therapy, responders and nonresponders.
Overall among the 34 patients enrolled in the study, the average headache frequency decreased from 18.6 of 28 to 9.9 of 28 days, P value, <0.001 from baseline. There was significant decrease in the average headache intensity, 8.1 to 4.3. Of 34 patients, 25 (73%) patients responded to treatment with decrease in headache frequency by ≥ 50% from the baseline. Among the nonresponder patients, a significant number of patients (six of nine, 67%) had generalized anxiety disorder with Generalized Anxiety Disorder-7 score greater than 15 versus the responder group (six of 25, 24%, P value 0.040).
BoNT-A remains a safe and effective therapy for adolescent and young adult patients with chronic migraines at nine months of follow-up. Generalized anxiety disorder with Generalized Anxiety Disorder-7 score greater than 15 can be a major predictor of poor response to this therapy.</description><identifier>ISSN: 0887-8994</identifier><identifier>EISSN: 1873-5150</identifier><identifier>DOI: 10.1016/j.pediatrneurol.2022.02.002</identifier><identifier>PMID: 35305510</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Anxiety Disorders - complications ; Botulinum toxin type A ; Botulinum Toxins, Type A - therapeutic use ; Child ; Generalized anxiety disorder ; Headache - drug therapy ; Humans ; Migraine ; Migraine Disorders - drug therapy ; Neuromuscular Agents - therapeutic use ; Pediatrics ; Retrospective Studies ; Treatment Outcome ; Young Adult</subject><ispartof>Pediatric neurology, 2022-05, Vol.130, p.21-27</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-df48e7656918650f1d31b77b3895710205dcde70263dbe002d39a1a28bd9279f3</citedby><cites>FETCH-LOGICAL-c383t-df48e7656918650f1d31b77b3895710205dcde70263dbe002d39a1a28bd9279f3</cites><orcidid>0000-0002-6056-2940</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0887899422000200$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35305510$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goenka, Ajay</creatorcontrib><creatorcontrib>Grace Yu, Sarah</creatorcontrib><creatorcontrib>Chikkannaiah, Mahesh</creatorcontrib><creatorcontrib>George, Monica Cathryn</creatorcontrib><creatorcontrib>MacDonald, Sarah</creatorcontrib><creatorcontrib>Stolfi, Adrienne</creatorcontrib><creatorcontrib>Kumar, Gogi</creatorcontrib><title>Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine</title><title>Pediatric neurology</title><addtitle>Pediatr Neurol</addtitle><description>To assess the efficacy, safety, and predictors for poor responsiveness of botulinum toxin type A (BoNT-A) for chronic migraine in the adolescent and young adult population.
A retrospective analysis of 56 patients who received BoNT-A for chronic migraine with an age range from 13 to 21 years was performed. Of 56 patients, 34 were enrolled in the study based on the inclusion criterion. Patients who received three dosages of BoNT-A were assessed at nine months from the first injection. Variables including age, body mass index, headache intensity, frequency, character, and side effects were assessed. The patients were divided into two groups based on response to BoNT-A therapy, responders and nonresponders.
Overall among the 34 patients enrolled in the study, the average headache frequency decreased from 18.6 of 28 to 9.9 of 28 days, P value, <0.001 from baseline. There was significant decrease in the average headache intensity, 8.1 to 4.3. Of 34 patients, 25 (73%) patients responded to treatment with decrease in headache frequency by ≥ 50% from the baseline. Among the nonresponder patients, a significant number of patients (six of nine, 67%) had generalized anxiety disorder with Generalized Anxiety Disorder-7 score greater than 15 versus the responder group (six of 25, 24%, P value 0.040).
BoNT-A remains a safe and effective therapy for adolescent and young adult patients with chronic migraines at nine months of follow-up. Generalized anxiety disorder with Generalized Anxiety Disorder-7 score greater than 15 can be a major predictor of poor response to this therapy.</description><subject>Adolescent</subject><subject>Anxiety Disorders - complications</subject><subject>Botulinum toxin type A</subject><subject>Botulinum Toxins, Type A - therapeutic use</subject><subject>Child</subject><subject>Generalized anxiety disorder</subject><subject>Headache - drug therapy</subject><subject>Humans</subject><subject>Migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>Neuromuscular Agents - therapeutic use</subject><subject>Pediatrics</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0887-8994</issn><issn>1873-5150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1v1DAQhi0EokvhLyBLXLhkO7bjxIbTUkqL1IoKLWcrsSfgVTYOdlJ1--txlVKpt0pj-_J-jB9CPjBYM2DVyW49ovPNFAecY-jXHDhfQx7gL8iKqVoUkkl4SVagVF0orcsj8ialHQBIzcvX5EhIAVIyWJG7cxwwNr2_Q0c3w63H6UC_-hSiw_iJbuh1zGV2CpF2-VyHfP3ENIYh-ZtsTYlOgX4J09z7Yd7Tbbj1A90eRsze7Z8cPR4W57Kzt_TK_46NH_AtedU1fcJ3D-8x-fXtbHt6UVz-OP9-urksrFBiKlxXKqwrWWmmKgkdc4K1dd0KpWXNgIN01mENvBKuxQzBCd2whqvWaV7rThyTj0vuGMPfGdNk9j5Z7PtmwDAnw6sStJZKlVn6eZHaGFKK2Jkx-n0TD4aBuYdvduYJfHMP30Ae4Nn9_qFobvfoHr3_aWfB2SLA_N0bj9Ek63GwOTGinYwL_llF_wDtF56k</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Goenka, Ajay</creator><creator>Grace Yu, Sarah</creator><creator>Chikkannaiah, Mahesh</creator><creator>George, Monica Cathryn</creator><creator>MacDonald, Sarah</creator><creator>Stolfi, Adrienne</creator><creator>Kumar, Gogi</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6056-2940</orcidid></search><sort><creationdate>202205</creationdate><title>Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine</title><author>Goenka, Ajay ; Grace Yu, Sarah ; Chikkannaiah, Mahesh ; George, Monica Cathryn ; MacDonald, Sarah ; Stolfi, Adrienne ; Kumar, Gogi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-df48e7656918650f1d31b77b3895710205dcde70263dbe002d39a1a28bd9279f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adolescent</topic><topic>Anxiety Disorders - complications</topic><topic>Botulinum toxin type A</topic><topic>Botulinum Toxins, Type A - therapeutic use</topic><topic>Child</topic><topic>Generalized anxiety disorder</topic><topic>Headache - drug therapy</topic><topic>Humans</topic><topic>Migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>Neuromuscular Agents - therapeutic use</topic><topic>Pediatrics</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goenka, Ajay</creatorcontrib><creatorcontrib>Grace Yu, Sarah</creatorcontrib><creatorcontrib>Chikkannaiah, Mahesh</creatorcontrib><creatorcontrib>George, Monica Cathryn</creatorcontrib><creatorcontrib>MacDonald, Sarah</creatorcontrib><creatorcontrib>Stolfi, Adrienne</creatorcontrib><creatorcontrib>Kumar, Gogi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goenka, Ajay</au><au>Grace Yu, Sarah</au><au>Chikkannaiah, Mahesh</au><au>George, Monica Cathryn</au><au>MacDonald, Sarah</au><au>Stolfi, Adrienne</au><au>Kumar, Gogi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine</atitle><jtitle>Pediatric neurology</jtitle><addtitle>Pediatr Neurol</addtitle><date>2022-05</date><risdate>2022</risdate><volume>130</volume><spage>21</spage><epage>27</epage><pages>21-27</pages><issn>0887-8994</issn><eissn>1873-5150</eissn><abstract>To assess the efficacy, safety, and predictors for poor responsiveness of botulinum toxin type A (BoNT-A) for chronic migraine in the adolescent and young adult population.
A retrospective analysis of 56 patients who received BoNT-A for chronic migraine with an age range from 13 to 21 years was performed. Of 56 patients, 34 were enrolled in the study based on the inclusion criterion. Patients who received three dosages of BoNT-A were assessed at nine months from the first injection. Variables including age, body mass index, headache intensity, frequency, character, and side effects were assessed. The patients were divided into two groups based on response to BoNT-A therapy, responders and nonresponders.
Overall among the 34 patients enrolled in the study, the average headache frequency decreased from 18.6 of 28 to 9.9 of 28 days, P value, <0.001 from baseline. There was significant decrease in the average headache intensity, 8.1 to 4.3. Of 34 patients, 25 (73%) patients responded to treatment with decrease in headache frequency by ≥ 50% from the baseline. Among the nonresponder patients, a significant number of patients (six of nine, 67%) had generalized anxiety disorder with Generalized Anxiety Disorder-7 score greater than 15 versus the responder group (six of 25, 24%, P value 0.040).
BoNT-A remains a safe and effective therapy for adolescent and young adult patients with chronic migraines at nine months of follow-up. Generalized anxiety disorder with Generalized Anxiety Disorder-7 score greater than 15 can be a major predictor of poor response to this therapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35305510</pmid><doi>10.1016/j.pediatrneurol.2022.02.002</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6056-2940</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-8994 |
| ispartof | Pediatric neurology, 2022-05, Vol.130, p.21-27 |
| issn | 0887-8994 1873-5150 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2640995884 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Anxiety Disorders - complications Botulinum toxin type A Botulinum Toxins, Type A - therapeutic use Child Generalized anxiety disorder Headache - drug therapy Humans Migraine Migraine Disorders - drug therapy Neuromuscular Agents - therapeutic use Pediatrics Retrospective Studies Treatment Outcome Young Adult |
| title | Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T13%3A36%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Generalized%20Anxiety%20Disorder:%20A%20Predictor%20for%20Poor%20Responsiveness%20to%20Botulinum%20Toxin%20Type%20A%20Therapy%20for%20Pediatric%20Migraine&rft.jtitle=Pediatric%20neurology&rft.au=Goenka,%20Ajay&rft.date=2022-05&rft.volume=130&rft.spage=21&rft.epage=27&rft.pages=21-27&rft.issn=0887-8994&rft.eissn=1873-5150&rft_id=info:doi/10.1016/j.pediatrneurol.2022.02.002&rft_dat=%3Cproquest_cross%3E2640995884%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640995884&rft_id=info:pmid/35305510&rft_els_id=S0887899422000200&rfr_iscdi=true |